StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the stock.
Moleculin Biotech Stock Performance
Shares of NASDAQ MBRX opened at $2.75 on Thursday. The firm has a 50 day moving average price of $2.60 and a 200 day moving average price of $4.01. Moleculin Biotech has a 52-week low of $2.12 and a 52-week high of $15.75.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, sell-side analysts forecast that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- Investing in Construction Stocks
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Differences Between Momentum Investing and Long Term Investing
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Best Stocks Under $10.00
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.